Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.

Fuxe K, Borroto-Escuela DO, Tarakanov AO, Romero-Fernandez W, Ferraro L, Tanganelli S, Perez-Alea M, Di Palma M, Agnati LF.

Prog Brain Res. 2014;211:113-39. doi: 10.1016/B978-0-444-63425-2.00005-2. Review.

PMID:
24968778
2.

Multiple D2 heteroreceptor complexes: new targets for treatment of schizophrenia.

Borroto-Escuela DO, Pintsuk J, Schäfer T, Friedland K, Ferraro L, Tanganelli S, Liu F, Fuxe K.

Ther Adv Psychopharmacol. 2016 Apr;6(2):77-94. doi: 10.1177/2045125316637570. Epub 2016 Mar 10. Review.

3.

Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.

Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84. doi: 10.1016/j.bbrc.2013.11.104. Epub 2013 Dec 2.

PMID:
24309097
4.

Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization.

Fuxe K, Tarakanov A, Romero Fernandez W, Ferraro L, Tanganelli S, Filip M, Agnati LF, Garriga P, Diaz-Cabiale Z, Borroto-Escuela DO.

Front Endocrinol (Lausanne). 2014 May 13;5:71. doi: 10.3389/fendo.2014.00071. eCollection 2014. Review.

5.

Cocaine self-administration differentially affects allosteric A2A-D2 receptor-receptor interactions in the striatum. Relevance for cocaine use disorder.

Pintsuk J, Borroto-Escuela DO, Pomierny B, Wydra K, Zaniewska M, Filip M, Fuxe K.

Pharmacol Biochem Behav. 2016 May;144:85-91. doi: 10.1016/j.pbb.2016.03.004. Epub 2016 Mar 14.

PMID:
26987369
6.
7.

Understanding the role of heteroreceptor complexes in the central nervous system.

Fuxe K, Borroto-Escuela D, Fisone G, Agnati LF, Tanganelli S.

Curr Protein Pept Sci. 2014;15(7):647.

PMID:
25256022
8.

Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation.

Weiss SM, Whawell E, Upton R, Dourish CT.

Neurology. 2003 Dec 9;61(11 Suppl 6):S88-93. Review.

PMID:
14663018
9.

Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease.

Fuxe K, Guidolin D, Agnati LF, Borroto-Escuela DO.

Expert Opin Ther Targets. 2015 Mar;19(3):377-98. doi: 10.1517/14728222.2014.981529. Epub 2014 Dec 8. Review.

PMID:
25486101
10.
11.

Effects of olanzapine and betahistine co-treatment on serotonin transporter, 5-HT2A and dopamine D2 receptor binding density.

Lian J, Huang XF, Pai N, Deng C.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Dec 2;47:62-8. doi: 10.1016/j.pnpbp.2013.08.005. Epub 2013 Aug 27.

PMID:
23994047
12.

Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.

Urigüen L, García-Fuster MJ, Callado LF, Morentin B, La Harpe R, Casadó V, Lluis C, Franco R, García-Sevilla JA, Meana JJ.

Psychopharmacology (Berl). 2009 Oct;206(2):313-24. doi: 10.1007/s00213-009-1608-2. Epub 2009 Aug 4.

PMID:
19652957
13.

Atypical antipsychotics: mechanism of action.

Seeman P.

Can J Psychiatry. 2002 Feb;47(1):27-38. Review.

PMID:
11873706
14.

Neurotensin NTS1-dopamine D2 receptor-receptor interactions in putative receptor heteromers: relevance for Parkinson's disease and schizophrenia.

Ferraro L, Beggiato S, Borroto-Escuela DO, Ravani L, O'Connor WT, Tomasini MC, Borelli AC, Agnati LF, Antonelli T, Tanganelli S, Fuxe K.

Curr Protein Pept Sci. 2014;15(7):681-90. Review.

PMID:
25175457
15.

Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function.

Fuxe K, Ferré S, Canals M, Torvinen M, Terasmaa A, Marcellino D, Goldberg SR, Staines W, Jacobsen KX, Lluis C, Woods AS, Agnati LF, Franco R.

J Mol Neurosci. 2005;26(2-3):209-20. Review.

PMID:
16012194
16.
17.

Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.

Wilson JM, Sanyal S, Van Tol HH.

Eur J Pharmacol. 1998 Jun 26;351(3):273-86. Review.

PMID:
9721018
18.

Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia.

Ferré S.

Psychopharmacology (Berl). 1997 Sep;133(2):107-20. Review.

PMID:
9342776
19.

Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferré S.

Neurology. 2003 Dec 9;61(11 Suppl 6):S19-23. Review.

PMID:
14663004
20.

Targeting the dopamine D2 receptor in schizophrenia.

Seeman P.

Expert Opin Ther Targets. 2006 Aug;10(4):515-31. Review.

PMID:
16848689
Items per page

Supplemental Content

Write to the Help Desk